Cantor Fitzgerald Reiterates Overweight Rating on Pacific Biosciences of California (PACB)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $2.50 price target on Pacific Biosciences of California (NASDAQ: PACB).

The analyst commented, “According to PACB, ~20% of the company's revenue is direct/indirect NIH-funded, which may result in an extended sale cycle as confusion around funding has risen. Additionally, Asia- Pacific is an important region for PACB, historically accounting for ~27% (3Q24) of total revenue. While we continue to believe PACB's shares are significantly undervalued, trading at 3.7x EV/CY25E revenue, given the capital funding environment, the state of biotech/pharma and now NIH/China concerns, we are cautious on PACB.”

For an analyst ratings summary and ratings history on Pacific Biosciences of California click here. For more ratings news on Pacific Biosciences of California click here.

Shares of Pacific Biosciences of California closed at $1.24 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy